SOUTH KINGSTOWN –MindImmune Therapeutics Inc. has entered into agreements with H. Lundbeck A/S to acquire programs and will develop candidates from these programs as novel therapeutics to treat neuropathic pain and Huntington’s disease, the company announced Wednesday. The programs target two neuroinflammation targets: P2X7 receptors and KMO, an enzyme in the neuroimmune kynurenine-signaling pathway, according…
Want More Free?
To access 2 more articles, please log in or register for free.
Registered users get access to a limited number of free articles every month.